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Abstract  13 
Context  14 
Carbohydrate restricted diets may increase low density lipoprotein-cholesterol and thereby 15 
cardiovascular risk.  16 
Objective  17 
A systematic review and meta-analyses was conducted to compare the effects of very low, low 18 
and moderate carbohydrate higher fat diets versus high-carbohydrate low-fat diets on low 19 
density lipoprotein-cholesterol and other lipid markers in overweight/obese adults.  20 
Data Sources   21 
Medline, PubMed, Cochrane Central, and CINAHL Plus were searched to identify large 22 
randomised controlled trials (n > 100) with duration ≥ 6 months.  23 
Data Extraction   24 
Eight randomised controlled trials (n = 1633, 818 carbohydrate restricted, 815 low fat diet) 25 
were included. 26 
Data Analysis 27 
Quality assessment and risk of bias, a random effects model, sensitivity and subgroup analysis 28 
based on the degree of carbohydrate restriction were performed using Cochrane Review 29 
Manager. Results were reported according to ‘Preferred Reporting Items for Systematic 30 
Reviews and Meta-Analysis Protocol’.  31 
Results 32 
Carbohydrate restricted diets showed a none significant difference in low density lipoprotein-33 
cholesterol after 6, 12, and 24 months. While an overall pooled analysis statistically favoured 34 
low-fat diets [0.07 mmol/L; 95% CI 0.02, 0.13; p = 0.009] this was clinically insignificant. 35 
High density lipoprotein-cholesterol and plasma triglycerides at 6 and 12 months, favoured 36 
carbohydrate restricted diets [0.08 mmol/L, 95% CI 0.06, 0.11; p < 1x10
-5
 and -0.13 mmol/L, 37 
95% CI -0.19, -0.08; p < 1x10
-5
] respectively. These favourable changes were more marked in 38 
the subgroup with very-low carbohydrate content (< 50 g/day) [0.12 mmol/L, 95% CI 0.10, 39 
0.14; p < 1x10
-5
 and -0.19 mmol/L, 95% CI -0.26, -0.12, p = 0.02] respectively.  40 
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Conclusions 41 
Large randomised controlled trials of at least 6 months duration with carbohydrate restriction 42 
appear superior in improving lipid markers when compared to low-fat diets. Dietary guidelines 43 
should consider carbohydrate restriction as an alternative dietary strategy for the 44 
prevention/management of dyslipidaemia for populations with cardiometabolic risk. 45 
 46 
Key words: low carbohydrate diet, low density lipoprotein cholesterol, lipid profile, 47 
cardiovascular disease, meta-analysis 48 
 49 
 50 
Introduction 51 
“All scientific work is incomplete – whether it be observational or experimental. All scientific 52 
work is liable to be upset or modified by advancing knowledge. That does not confer upon us a 53 
freedom to ignore the knowledge we already have, or to postpone the action that it appears to 54 
demand at a given time”. 55 
Austin Bradford Hill 56 
The galloping global and upward trend in obesity/overweight prevalence and the epidemics of 57 
non-communicable diseases
1
 is raising concern regarding the efficiency of existing dietary 58 
recommendations. Questions on the strength of the evidence on which these recommendations 59 
are based
2,3
 as well as the role of saturated fatty acids (SFA), polyunsaturated fatty acids 60 
(PUFA), and refined carbohydrates in the on-set of cardiovascular disease (CVD) have 61 
historically been and continue to be debated.
4-9
 Recently, an ample amount of evidence 62 
suggests that carbohydrate restricted diets (CRDs) including low, moderate, and very low 63 
carbohydrate ketogenic diets (LCD, MLCD, VLCD respectively) have the potential to improve 64 
various metabolic pathways with the added beneficial effects in treatment of 65 
overweight/obesity, and in amelioration of cardiometabolic risk markers.
9-14
 VLCD are often 66 
interchangeable with the terminology, ‘ketogenic diet’ (KD). The underlying mechanism of a 67 
KD is reduction in the levels of circulating insulin along with increased levels of glucagon due 68 
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to scarcity of dietary carbohydrates, leading to a reduction in lipogenesis and fat 69 
accumulation.
15-17
 This results in an increased mobilization of fatty acids from adipocytes and 70 
overproduction of ketone bodies, which are used as an alternative fuel to glucose by the extra-71 
hepatic tissues such as the brain and the muscle.
15-18
 Ketone bodies also reduce the catabolism 72 
of lean body mass, which in large explains the preservation of lean tissue observed during very 73 
low carbohydrate dieting.
12,19
  74 
The main concern regarding CRDs, which are potentially high in total and SFA, is their 75 
theoretically adverse effect on low density lipoprotein-cholesterol (LDL-C) levels and 76 
presumably, CVD risk. Saturated fat per se is not associated with increased CVD risk, as 77 
concluded in several recent meta-analyses and systematic reviews
6,20,21
 due, to some extent, to 78 
the differential effects of saturated fat on LDL subclass concentrations. Namely, cholesterol-79 
enriched large buoyant LDL particles (lbLDL) have shown to be less atherogenic, while small 80 
dense (sdLDL) and medium sized LDL particles more strongly associate with CVD 81 
outcomes.
22-26
 Data suggest that a shift towards lbLDL occurs among participants following a 82 
CRD, resulting in a decreased CVD-risk, while the opposite occurs among those on high-83 
carbohydrate diets.
27
  However, the role of low-carbohydrate ketogenic diets in the long-term 84 
management of obesity and cardiometabolic risk markers is not well established. Data from 85 
recent systematic reviews and meta-analyses regarding LDL-C are very contradictory. While 86 
some find an increased level,
28-30
 others report non-significant changes
31
 or decreased levels
32
 87 
of LDL-C in subjects following CRD compared to those on a low fat diets (LFD).  88 
Due to the lack of consensus on the effects of CRD on LDL-C between these findings, authors 89 
have been very cautious in making recommendations for or against them. This has also led to 90 
deepening the disagreement among experts
2
 and further uncertainty for the public especially 91 
regarding the long-term effectiveness of CRDs, pointing towards the need to further reconsider 92 
and evaluate the existing scientific evidence. The lack of consensus could be partially assigned 93 
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to the heterogeneity of the CHO content in interventions as definitions of CRDs differ,
14
 and/or 94 
in inclusion and exclusion criteria used during the selection procedures of performed meta-95 
analyses. For example, some meta-analyses include trials of both healthy and diabetic 96 
patients
32
 and many report only the pooled net effect of large and small trials without 97 
stratification by duration of intervention or follow up.
28-30
 Small studies may overestimate 98 
intervention effects, introduce higher heterogeneity and increase risk of selection bias
33-36
 99 
while larger studies are considered to have more power to detect differences in observed 100 
outcomes and are more likely to generate conclusions that can be generalised
37
. Based on these 101 
limitations, Santos et al.
38
 performed a meta-analysis of randomised controlled trials (RCTs) 102 
with at least 100 overweight/obese healthy participants. This study reports an initial increase of 103 
LDL-C in the period 0-6 months, followed by a significant decrease at 12 and 24 months, and 104 
overall significantly favourable effect of the CRD on the main cardiometabolic risk markers. 105 
Though well designed and important, the limitation of this meta-analysis lies in the fact that 106 
the final effects are compared to the baseline values with no comparison against LFDs.    107 
In light of these shortcomings and contradictory findings, the aim of this systematic review and 108 
meta-analysis is to compare the effects of CRD and LFD on LDL-C and other lipid markers in 109 
overweight/obese adults, using data obtained from large RCTs with at least 6 months’ duration. 110 
This research also pertains to suggest the choice of diet that would be most effective for 111 
prevention and management of dyslipidaemia in population groups at higher risk of 112 
cardiovascular disease (e.g. obesity, overweight, metabolic syndrome, type 2 diabetes) and to 113 
contribute to the discussion about whether current dietary guidelines should be reconsidered 114 
and adapted to the latest evidence.  115 
Methods  116 
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This systematic review and meta-analysis is performed and reported according to the Preferred 117 
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement
39
 (Appendix 118 
S1) and the PICOS (Population, Intervention, Comparison, and Outcomes) (Table 1) criteria 119 
were used to define the following research question: Do long-term carbohydrate restricted, 120 
higher-fat diets have an adverse effect on LDL-C levels and presumably CVD risk among 121 
overweight/obese adults? 122 
Search methods 123 
The following databases were searched for relevant RCTs published between January 1970 124 
and June 2017 with no restriction on language: Medline (EBSCO), PubMed, Cochrane Central, 125 
and CINAHL Plus. These databases were searched individually with advanced search 126 
strategies using various combinations of filters and controlled vocabulary in relation to both 127 
carbohydrate restricted diets and low fat diets in order to enhance precisions and sensitivity 128 
(Appendix 2.  Furthermore, previous relevant meta-analyses, systematic reviews, and selected 129 
randomised controlled trials were manually searched for studies that met the 130 
inclusion/exclusion criteria. 131 
Inclusion criteria and data abstraction 132 
RCTs included in this research were required to compare the effects of carbohydrate restricted 133 
diets (CRD) (defined as ≤ 45% total energy intake (TEI) from CHO, including MLCD ≤ 45% -134 
>26% TEI or 130 – 225 g, LCD as 10 - < 26% TEI or 50 – 130 g, and VLCD as < 10% TEI or 135 
< 50 g,  and > 35% TEI from fat, fed ad libitum) versus a LFD (defined as ≤ 35% TEI from fat 136 
and ≥ 50% TEI from CHO, and restriction on total energy intake)
40,41
 with outcomes on 137 
serum/plasma LDL-C and other lipid profile markers, namely total cholesterol (TC), high 138 
density lipoprotein-cholesterol (HDL-C) and triglycerides (TG), published between 1970 and 139 
June, 2017. Large randomised controlled trials with duration of at least six months and with at 140 
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least 100 randomised adult participants (18-65 years) at the start of the dietary intervention, 141 
with a body mass index (BMI) > 25 kg/m
2
 were included. The decision to include RCTs ≥ 6 142 
months was based on the differential effects on LDL-C in shorter term versus longer term 143 
studies and lack of comparison to low fat diets at this duration, i.e. compared to baseline,  144 
LDL-C increases at 6 months but decreases at 12 and 24 months.
38
 145 
Exclusion criteria 146 
To increase power, reduce heterogeneity, and selection bias, 
33-35,37
, trials with a study 147 
population < 100 randomised participants were excluded. Trials with a specific pathology 148 
rather than obesity (such as diabetes, cancer, kidney or coronary heart disease), altered 149 
endocrinological state (such as pregnancy, lactation or menopause), trials with a duration < 6 150 
months and trials which did not report standard deviation (SD) or 95% confidence intervals 151 
(CI) were also excluded. 152 
Data extraction and quality assessment 153 
In order to minimise potential bias during selection procedure, the duplicates of full articles 154 
retrieved for further assessment were independently read by two reviewers (T.G.H and R.A.B) 155 
to make a consent decision for inclusion. From studies with more than two interventions, the 156 
most suitable dietary interventions were chosen for comparison. The following data were 157 
collected: title, first author, year of publication, country, design of RCT (parallel, cross-over, 158 
factorial), blinding of participant and personnel (open, single, double), baseline characteristics 159 
of study participants such as age, sex, BMI, and total number of randomised participants, 160 
health status, and baseline LDL-C, HDL-C, TG and TC values, composition of diet, attrition, 161 
handling of missing data and overall and subgroup mean difference in outcomes with measures 162 
of variance (SD or 95% CI). The Cochrane Collaboration tool
42
 was used for assessing 163 
methodological quality and risk of bias with the following categories: selection bias (random 164 
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sequence generation, allocation concealment), performance bias (blinding of participants and 165 
personnel and blinding of the outcome assessment), reporting bias (selective outcome 166 
reporting), and other biases. Publication bias was assessed with funnel plots. Disagreements 167 
were resolved by discussion and by seeking the opinion of the third independent reviewer 168 
(I.G.D.), as required by the PRISMA statement.
39
 169 
Data synthesis and data analysis 170 
Extracted data from eligible studies were first tabulated by outcome of interest and presented 171 
in mmol/L; data expressed in mg/dL were converted into mmol/L by multiplying the values 172 
with the factor 0.0259 for cholesterol and its fractions, and the factor 0.013 for conversion of 173 
TG. In studies reporting mean values and 95% CI, the SD was calculated. Intervention effects 174 
across trials were pooled to calculate weighted mean differences and the 95% CI for each 175 
continuous outcome (LDL-C, HDL-C, TG, TC) between baseline and 6, 12 and 24 months of 176 
intervention duration. The CRD arm was also divided into two subgroups based on the CHO-177 
content: very low-carbohydrate diet (VLCD) with < 10% CHO TEI (< 50 g CHO) and 178 
moderate low-carbohydrate diet (MLCD) with 26-45% CHO TEI (130 – 225 g CHO).
43
 179 
Subgroup analyses were performed when possible in order to explore the potential effect of 180 
different CHO content on the primary and secondary outcome estimates. It is important to note 181 
that studies classified as low carbohydrate diets (LCDs) (10 – < 26% CHO TEI (50 – 130 g 182 
CHO)) which would fulfil the inclusion criteria were not identified. The Random Effects 183 
Model was used to account for heterogeneity in design and outcome variables, as the 184 
heterogeneity is incorporated in the total weighted efficacy of treatment, allowing for a greater 185 
variability of the estimate.
44
  Heterogeneity and inconsistency (I
2
) was calculated with the 186 
Cochran Q test. I
2
 values > 50% and > 75% indicated moderate and high heterogeneity 187 
respectively.
42
 In order to evaluate the relative influence on the pooled estimated effects, a 188 
sensitivity analysis was conducted by excluding studies that had less than 70% completion 189 
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rate, studies with a very low-fat diet, studies that were performed on women only, and on those 190 
with the lowest mean age of participants. For detecting the existence of publication bias and its 191 
possible effect on the performed meta-analysis, funnel plots as the most common method were 192 
used. All statistical analyses were performed using Review Manager (RevMan 5.3.5). 193 
Results 194 
Literature search 195 
The flow of the study selection procedure which followed the literature search is summarised 196 
in Figure 1. Potential relevant records (308) were identified during the search of the databases 197 
and additional 17 were identified from screening of references. After initial screening and 198 
duplicate removal 252 records remained, of which 205 were excluded on the bases of 199 
interrogation of abstracts, and 47 full-text articles were retrieved for detailed review.  Thirty-200 
nine full-text records did not fulfil the set inclusion criteria and, after their removal, 8 RCTs 201 
remained eligible to be included in the meta-analysis. The reasons for exclusion of the 39 full-202 
article trials are presented in Table 2
45-83
. Five trials
45-49
 did not include LDL-C as an outcome; 203 
ten trials
50-59
 were performed on participants with Diabetes mellitus and/or CVD; eleven 204 
trials
60-70
 had less than 100 randomised participants; three
71-73
 had duration < 6 months; two 205 
trials
74,75
 did not report on SD or 95% CI; seven trials
76-82
 were irrelevant with inappropriate 206 
intervention; and one trial
83
 was dismissed based on high attrition rate and high risk of bias. 207 
Study and participant characteristics 208 
The main characteristics of the eight published articles eligible for meta-analysis are 209 
summarised in Table 3
84-91
. All eight RCTs were open and parallel group trials with no 210 
possibility for blinding of participants due to the polarity of diets. Intervention duration ranged 211 
from 6 to 24 months. Most of the trials offered some form of supportive dietary sessions and 212 
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professional contact and participants were encouraged to engage and maintain a certain level of 213 
physical activity. However, none reported any record of the level of physical activity. Trials 214 
were conducted on both sexes with a higher proportion of female participants, except for the 215 
study by Gardner et al.
88
 which was performed only on women. The mean age and BMI of 216 
participants varied from 28.2 - 51.5 years, and 31.4 – 36.1 kg/m
2
 respectively. All 8 trials
84-91
 217 
with a total of 1633 participants (n = 818 on CRD, n = 815 on LFD) reported 6 months follow 218 
up; 5 trials with a total of 1010 participants (n = 505 on CRD, n = 505 on LFD) reported 12 219 
months outcome measures
84,86,87,89,90
 and 2 studies with a total of 715 (n = 357 on CRD, n = 220 
358 on LFD) reported data for 24 months.
86,91
 According to the CHO content, the CRD 221 
intervention was divided into two subgroups: VLCD and MLCD (Table 3). The VLCD-222 
subgroup consisted of four trials: three trials
86,88,90
 followed the Atkins diet (Dr. Atkins New 223 
Diet Revolution, 1998)
92
, defined as < 20 g/d of CHO for the first three months, with a gradual 224 
increase of 5 g/d after the third month up to 50 g/d CHO, while in one trial
84
 the CHO intake 225 
was restricted to < 40 g of CHO daily. The other 4 trials
85,87,89,91
 restricted the CHO 226 
consumption to about 35-40% of the total daily energy, making up the MLCD subgroup. CRD 227 
interventions were ad libitum in all trials regarding energy intake, but some studies reported a 228 
spontaneous reduction of energy intake.
87,88,90
 LFD interventions permitted 50-65% of energy 229 
from CHO and 20 - < 35% of energy deriving from fat across all trials, except for the trial of 230 
Gardner et al.
88
 with a very low  fat (< 10%) high CHO (70%) intervention (Ornish) diet.
93
 231 
Diet compliance was measured via three 24 h dietary recalls
84,87,88,91
 or 7-day food 232 
diaries.
86,89,90
 In the study of Due et al.
85
 dietary intake and compliance was assessed by fat 233 
biopsy, while food was available from a custom made supermarket for the purpose of the trial 234 
with supervised shopping. Attrition rate showed large variation, with dropout rates ranging 235 
from 12-44%.   All studies had applied Intention-to-treat analysis for the missing data. (Table 236 
3). Reported baseline mean levels of LDL-C, HDL-C, TG, and TC varied across trials and 237 
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intervention, but were well balanced in both the CRD and LFD arm of intervention in each 238 
study (Table 4
84-91
).  239 
LDL-C concentrations were directly measured except in the trials of Bazzano et al.
84
 and Due 240 
et al.
85
 where it was calculated using the Friedewald formula.
94
 In the study of Klemsdal et 241 
al.
89
 the assessment of LDL-C was not clearly stated. Three studies evaluated additional lipid 242 
profile markers that are of interest to the primary outcome: changes in LDL-peak density (g/L) 243 
reported by Morgan et al.
90
, apolipoprotein-B concentration in the trial of Klemsdal et al.,
89
 244 
and concentration of the very low density lipoprotein cholesterol (VLDL-C) fraction in the 245 
study of Foster et al.
86
 246 
Quality assessment and risk of bias 247 
The quality and the risk of bias (%) across all included studies were assessed using the 248 
Cochrane Risk of Bias Tool and are presented in Figures 2 & 3
84-91
. Three studies did not 249 
clearly report on the sequence generation
89-91
 and allocation concealment
86,89,90
 used. Blinding 250 
of participants was impossible due to the nature of the trial. In addition, there was no blinding 251 
of the outcome assessors reported, but considering the fact that all outcomes are objective, it is 252 
unlikely that this has influenced the results of the RCTs. There was no evidence of selective 253 
reporting and five trials
84-88
 showed low risk of attrition bias. Four studies
86,89-91
 were judged to 254 
have a low risk of bias and no study received an overall score of ‘high’ in any assessed risk of 255 
bias category. 256 
Meta-analyses  257 
Effects of CRD and LFD on LDL-Cholesterol levels 258 
Results from the primary meta-analysis regarding the mean difference of LDL-C concentration 259 
between CRD and LFD intervention at 6, 12, and 24 months (compared to baseline) are 260 
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presented in Figure 4
84-91
 & Table S1. Although participants on the CRD intervention 261 
experienced a greater increase in LDL-C compared to the LFD, these changes are statistically 262 
non-significant regardless of intervention duration [6 months: 0.08 mmol/L; 95% CI -0.01, 263 
0.18; P = 0.08], [12 months: 0.04 mmol/L; 95% CI -0.04, 0.12; P = 0.37] and [24 months: 0.10 264 
mmol/L; 95% CI -0.01, 0.21; P = 0.06]. However, analysis of the global pooled effect between 265 
CRD and LFD interventions on LDL-C levels shows a significant weighted mean difference in 266 
favour of the LFD [0.07 mmol/L; 95% CI 0.02, 0.13; P = 0.009].   Significant (moderate) 267 
heterogeneity (I
2
 = 58%; P = 0.009) for the estimated difference of LDL-C between both diets 268 
was observed only at 6 months. Sensitivity analysis (exclusion of studies one by one) was 269 
carried out to identify the possible studies that could explain this heterogeneity. After 270 
exclusion of the study of Foster et al.,
86
 which had the highest weight effect, the heterogeneity 271 
considerably decreased (I
2
 = 28%, P = 0.22), but did not significantly change the weighted 272 
mean difference of LDL-C (P = 0.25). However, exclusion of the study of Due et al.,
85
 did not 273 
change the heterogeneity, but resulted with a statistically significant mean difference of LDL-C 274 
at 6 months in favour of the LFD (I
2
 = 58%, P = 0.04). This is possibly because it is the 275 
smallest study and/or has the lowest mean age of participants of 29.8 (Table 3). 276 
Subgroup analyses were performed to explore the possible influence of the CHO-content of the 277 
CRD intervention on LDL-C levels compared to the LFD-interventions. The very low 278 
carbohydrate subgroup (VLCD) with < 10% CHO TEI (Figure 5
84,86,88,90
 & Table S2) and the 279 
moderate carbohydrate subgroup (MLCD) with 35–45% CHO TEI (Figure 6
85,87,89,91
 & Table 280 
S3) did not cause any significant difference of LDL-C compared to the LFD regardless of 281 
duration of intervention. Both CRD-interventions, the VLCD and the MLCD, resulted with an 282 
overall non-significant mean change of LDL-C compared to the LFD-intervention and values 283 
were similar to the primary meta-analysis [for VLCD: 0.07 mmol/L; 95% CI -0.05, 0.18; 284 
P=0.27 and for the MLCD: 0.05 mmol/L; 95% CI -0.02, 0.12; P=0.16]. 285 
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Effects of CRD and LFD on HDL-C and Triglycerides levels 286 
The pooled global mean differences for HDL-C [HDL-C:  0.08 mmol/L, 95% CI 0.06, 0.11; P 287 
< 1x10
-5
] (Figure 7
84-91
   & Table S1) and TG [-0.13 mmol/L, 95% CI -0.19, -0.08; P < 1x10
-5
] 288 
(Figure 8
84-91
   & Table S1) showed an overall more favourable total effect of the CRD 289 
intervention. However, the mean differences for both parameters were significant at 6 months 290 
[HDL-C:  0.09 mmol/L, 95% CI 0.06, 0.12; P < 1x10
-5
 and TG: -0.18 mmol/L, 95% CI -0.25, -291 
0.11; P < 1x10
-5
] and 12 months [HDL-C:  0.09 mmol/L, 95% CI 0.02, 0.15; P = 0.008   and 292 
TG: -0.11 mmol/L, 95% CI -0.18, -0.03; P = 0.005], but non-significant at 24 months [HDL-C:  293 
0.05 mmol/L, 95% CI -0.00, 0.11; P = 0.06]  and [TG: 0.01 mmol/L, 95% CI -0.12, 0.13; 294 
P=0.93]. High heterogeneity of 74% was observed for HDL-C at 12 months, which was 295 
considerably decreased after removal of the trial of Frisch et al.
87
 without affecting the 296 
significance of the weighted mean difference (I
2
 = 45%; P < 1x10
-4
). 297 
The VLCD (Figure 9
84,86,88,90
    & Table S2) showed a greater increase of HDL-C compared to 298 
the LFD throughout the entire observed period [for 6 months: 0.13 mmol/L, 95% CI 0.09, 299 
0.16; P = 1x10
-5
; for 12 months: 0.13 mmol/L, 95% CI 0.09, 0.17; P = 1x10
-5
 and for 24 300 
months: 0.08 mmol/L, 95% CI 0.02, 0.14; P = 0.01]. Regarding TG concentration, the VLCD 301 
was more favourable at 6 months [-0.24 mmol/L, 95% CI -0.32, -0.16; P = 1x10
-5
] and 12 302 
months [-0.16 mmol/L, 95% CI -0.25, -0.06; P = 0.002] of the diet intervention, levelling its 303 
effect with the LFD group at 24 months [0.02 mmol/L, 95% CI -0.16, 0.02; P = 0.82] (Figure 304 
10
84,86,88,90
  & Table S2). Compared to the LFD, the MLCD showed more favourable effects 305 
regarding HDL-C and TG only for the initial period of 6 months of intervention duration 306 
respectively [HDL-C: 0.06 mmol/L, 95% CI 0.02, 0.10; P = 0.002] and [TG: -0.09 mmol/L, 307 
95% CI -0.18, 0.0; P = 0.05] (Figures 11
85,87,89,91
, 12
85,87,89,91
,
 
& Table S3).  Based on the 308 
overall total effect, the subgroup analyses showed that the VLCD was more effective than the 309 
Page 12 of 59Nutrition Reviews
13 
 
MLCD for HDL-C and TG, suggesting that the amount of CHO in CRD interventions plays an 310 
important role and its effect depends on the duration of intervention (Table S2 & S3).   311 
Effects of CRD and LFD on Total Cholesterol levels 312 
TC as an outcome was reported only in six studies
84-87,89,91
, which did not permit a meaningful 313 
subgroup analyses based on the CHO content of CRD interventions. The primary meta-314 
analysis for the estimated mean difference of total cholesterol level (Figure 13)
84-87,89,91
 & 315 
Table S1 revealed a negligible, but nevertheless more favourable significant effect of the CRD 316 
in the initial 6 months period [-0.01 mmol/L, 95% CI -0.01, -0.00; P = 0.02]. It is worth noting 317 
that though the estimated mean difference at 12 months was identical to the 6 month value, it 318 
showed to be statistically insignificant [-0.01 mmol/L, 95% CI -0.04, 0.3; P=0.78]. Both diets 319 
seemed to show no effect on total cholesterol level after 24 months of intervention [-0.00 320 
mmol/L, 95% CI -0.01, 0.00; P = 0.66]. The combined total effect of all studies was 321 
statistically in favour of the CRD intervention but clinically meaningless [-0.00 mmol/L, 95% 322 
CI -0.01, 0.00; P = 0.002].  323 
Effects of CRD and LFD on lipid markers not included in the meta-analysis 324 
Results of the LDL-peak density in the trial of Morgan et al.
90
 showed that after six months of 325 
intervention, this variable decreased within both dietary groups included in this RCT. 326 
However, the decrease of the LDL-peak density indicating an increase in LDL particle size 327 
was significantly greater than the control (no intervention group) only among participants on 328 
the VLCD diet. No significant changes of apolipoprotein-B after 12 months were found within 329 
and between dietary intervention groups in the trial of Klemsdal et al.
89
  Decreases in VLDL-C 330 
levels reported by Foster et al.
86
 were significantly greater in the CRD than in the LFD group 331 
at 6 months [LFD: -0.12 mmol/L; 95% CI -0.17, -0.08 vs CRD: -0.23 mmol/L; 95%CI -0.27, -332 
0.19; P < 0.001] and 12 months [LFD: -0.09 mmol/L; 95% CI -0.16, -0.02 vs CRD: -0.21 333 
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mmol/L; 95% CI -0.27, -0.19; P = 0.009], but non-significant differences were found at 24 334 
months [LFD: -0.05 mmol/L; 95% CI -0.12, -0.004 vs CRD: -0.05 mmol/L; 95%CI -0.12, -335 
0.0007; P = 0.99] 336 
Funnel Plots and Publication Bias  337 
Upon visual inspection, all three funnel plots (Figures S1-3) appeared to be approximately 338 
symmetrical, therefore no evidence of publication bias was found. However, the small number 339 
of studies included in this meta-analysis means that the funnel plots must be interpreted very 340 
cautiously, and the possibility of publication bias cannot be ruled out. 341 
Discussion 342 
The present meta-analysis of large randomised controlled trials with duration of at least six 343 
months compared the effects of CRDs with different CHO content versus LFD on LDL-C 344 
levels as a primary outcome, and HDL-C, TG and TC as secondary outcomes. The primary 345 
meta-analysis of the effects of CRDs and LFD on LDL-C levels showed an overall significant 346 
weighted mean difference in favour of the LFD despite the non-significant changes at 6, 12 347 
and 24 months of intervention duration (Figure 4). However, the subgroup analysis of LDL-C 348 
levels based on the CHO content of the CRD arm (Figures 5 & 6), showed non-significant net 349 
changes for both the VLCD and the MLCD diets throughout the whole observed period (6, 12 350 
and 24 months). Further, participants on CRDs experienced negligible changes of TC levels 351 
after 6 months (Figure 13) and more favourable changes on HDL-C and TG at 6 and 12 352 
months (Figures 7 & 8) resulting in overall more favourable net effects of CRDs compared to 353 
the LFD regarding these lipid markers. The comparison between VLCD and MLCD subgroups 354 
revealed the VLCD showed a marked increase and decrease of HDL-C and TG respectively 355 
(Figures 9-12). It is worth noting, however, that the analyses with a follow up of 24 months 356 
included only two trials.  357 
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The more favourable changes in several lipid parameters (HDL-C and TG) and non-significant 358 
changes of LDL-C in both the VLCD and MLCD subgroup analysis, despite the slight global 359 
increase in LDL-C, support the view that carbohydrate restriction, especially the VLCD, is 360 
more effective in improving investigated CVD risk markers. The presented findings with 361 
regard to LDL-C, HDL-C and TG weighted mean changes are relatively consistent with the 362 
findings of several other meta-analyses,
28,32,95
 all concluding that CRDs are at least as 363 
beneficial as the LFD and thus proposing CRDs as an alternative tool for treatment of 364 
metabolic risk and obesity. These findings are also in line with the most recent meta-analyses 365 
by Mansoor et al.
29
 and Lu et al.
30
 investigating the effects of a CRD vs LFD on cardiovascular 366 
risk markers. While the Lu et al.
30
 study showed an increase in LDL-C of 0.11 mmol/L (95% 367 
CI 0.205, 0.026) with the CRD, the authors emphasised the beneficial HDL-C raising effect of 368 
the CRD of 0.066 mmol/L (95% CI, 0.10, 0.033) equating to a 7.45% reduction in relative risk 369 
of CVD.  However, Mansoor et al.
29
 found an overall increase in LDL-C level of 0.16 mmol/L 370 
(95% CI 0.003, 0.33) with the CRD and highlighted its possible detrimental effect on CVD, 371 
stating this may outweigh the benefits of the increased HDL-C and decreased TG levels 372 
observed. The results of the present study show the inverse; the overall increase in LDL-C of 373 
0.07 mmol/L (95% CI 0.02, 0.13) with the CRD in the primary meta-analysis equates to a 374 
1.54% relative risk reduction in cardiovascular events.
96
 With HDL-C the pooled increase of 375 
0.08 mmol/L (95% CI 0.06, 0.11) reduces relative risk by 4.6% (using the latest evidence from 376 
the European Atherosclerosis Society).
97
 Furthermore, the lack of significant difference for 377 
LDL-C at 6, 12 and 24 months and in the VLCD and the MLCD-subgroup analysis supports a 378 
negated risk of CVD from LDL-C. These differences are presumably due to the different 379 
inclusion/exclusion criteria during the selection process between the current and the two 380 
previous meta-analyses.
29,30
 381 
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Targeting LDL-C has been a conventional strategy in prevention and treatment of CVD and 382 
reduction of mortality rate
98,99
 using statins that inhibit the 3-hydroxy-3-methylglutaryl-CoA 383 
(HMG-CoA) reductase activity which decreases hepatic cholesterol production and 384 
upregulation of the LDL-receptor.
100
 However, the reduction of CVD risk accomplished with 385 
this strategy, as it has been reported in several clinical trials,
101,102
 is no more than 30%. The 386 
main limitations of this strategy lies in the observed atherosclerotic complications among 387 
participants even after reaching acceptable LDL-C goals
103
 which is indicative of the presence 388 
of other risk factors beyond LDL-C that should be considered.  389 
Extensive evidence has shown that parameters which take into consideration the role of 390 
triglyceride-rich remnant lipoproteins or non-HDL-C as an indicator of cholesterol within all 391 
the apolipoprotein-B (apo-B) particles (including LDL, VLDL, Lp(a), and to some extent, 392 
intermediate-density lipoprotein, chylomicrons, and chylomicron remnants) are superior to 393 
LDL-C in quantifying the atherogenic properties of lipoproteins.
104,105
 In that context, non-394 
HDL-C, TG, and the TC/HDL-C ratio are more strongly associated with increased CVD risk 395 
than LDL-C, as depicted in several prospective studies such as: the Lipid Research Clinics 396 
Program Longitudinal Follow-up Study with over 19 years of follow-up of CVD risk and 397 
mortality rate
106
; the Framingham Offspring Study
107
; the 11 year follow up of the EPIC 398 
(European Prospective Investigation Into Cancer and Nutrition) Norfolk prospective 399 
population study.
108
 This study quantified the risk associated with these lipid parameters for 400 
each level of LDL-C, from low (< 2.59 mmol/L (100 mg/dL)) to high (> 4.14 mmol/L (160 401 
mg/dL)) in non-fasting samples.
108
 In addition, analysis of pooled data from nine RCTs on 402 
subjects with coronary artery disease undergoing serial intravascular ultrasonography, reports 403 
that the lower TC/HDL-C ratio lowers the risk of major adverse cardiovascular events and 404 
lower coronary atheroma progression rates.
109
 The above evidence points to the residual risk 405 
when LDL-C lowering treatments have failed to reduce cardiovascular events, and recent 406 
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review articles suggest focus should turn to drug or diet treatment other than LDL-C 407 
lowering.
110,111
  In the light of these consistent findings, it has been proposed that non–HDL-C 408 
be routinely used as a cost effective target in prevention and treatment of CVD risk.
109,112
  409 
Thus, when assessing the CVD risk of this negligible  increase in total LDL-C concentration 410 
produced by the CRDs, the marked increase in HDL-C in parallel to a marked decrease of TG 411 
with an overall neutral effect on TC, as found in the current meta-analysis, must be 412 
acknowledged.  413 
The strategy to target LDL-C concentration as a primary CVD risk marker also disregards the 414 
heterogeneity of LDL-particle number (LDL-P) and size as a function of atherogenecity, an 415 
important indicator particularly when LDL-C is not elevated.  Namely, sdLDL particles 416 
(phenotype B) are more strongly associated with CVD outcomes than the lbLDL particles 417 
(phenotype A).
24,25,113,114
 sdLDL particles are characterised by a longer plasma residence time, 418 
which results in higher particle oxidation and glycation, further reduction in size and increased 419 
accumulation within arterial intima.
26,113
 Increased concentrations of sdLDL particles produced 420 
by delipidated larger atherogenic VLDL and large LDL, and direct de novo hepatic production, 421 
correlate with increasing TG and decreasing HDL-C levels.
25
 Hence, increased TG 422 
concentration and higher TG/HDL-C ratios are superior predictors of an increasingly 423 
atherogenic LDL phenotype (phenotype B) than LDL-C, as it indicates higher levels of 424 
remnant lipoprotein particle cholesterol along with higher non-HDL-C and LDL density.
114,115
 425 
Further, recent evidence suggests that apo-B and LDL-P concentration are superior to LDL-C 426 
and non-HDL-C for assessment of CVD risk,
116
 particularly among subjects with metabolic 427 
syndrome and insulin resistance, as found in the Framingham Heart Study
117
 and in the cohort 428 
of the Quebec Cardiovascular Study.
118
 The concordance/discordance analysis of plasma apo-429 
B and LDL-P in two large retrospective cohorts shows that the discordance of LDL-P > apo-B 430 
is associated with sdLDL particle size, insulin resistance and increased systemic 431 
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inflammation.
119
 Evidence regarding the effect of CRDs on LDL-P size and apo-B in the 432 
published literature is scarce, which was also revealed during this study. In the presented 433 
systematic review, decreased LDL-peak density were reported by Morgan et al.
90
 only among 434 
participants following the Atkins diet when compared to the control, while decreased VLDL-C 435 
concentrations were found by Foster et al.
86
 These findings, though in favour of the VLCD, are 436 
not yet sufficient to make a meaningful judgement, as more large RCTs with longer duration 437 
are necessary in order to compare and critically discuss these variables. However, the results of 438 
the RCT conducted by Sharman et al.
120
 show that a short-term (6 week) hypoenergetic VLCD 439 
(< 10% CHO TEI) led to improvement of cardiometabolic risk factors: increased mean and 440 
peak LDL-P size along with fasting serum TG, TG/HDL-C ratio, postprandial lipaemia, serum 441 
glucose and insulin resistance in overweight men.
120
 Similar findings, namely, increase in peak 442 
LDL-P size, a shift towards lbLDL in participants who started with a predominance of sdLDL-443 
P, and overall improvement of CVD and diabetic risk markers after a 6 week KD-intervention 444 
in normolipidaemic men with normal body weight
121
 and after 12 weeks in subjects with 445 
atherogenic dyslipidaemia
11
 were found. 446 
The main argument against low-carbohydrate high-fat diets is the potential adverse effect on 447 
the TC and LDL-C levels as a result of a relative or absolute increase in dietary SFA due to 448 
CHO restriction,
4,7,14
 although the magnitude of the effect shows variations in constellation to 449 
the specific diet quality and individual susceptibility.
5,122,123
  Macronutrient dietary content 450 
with SFA intake is almost unavoidable, because these fatty acids are present in all fat-451 
containing foods (dairy products, meats, egg yolk, and in some vegetable fats and oils). SFA 452 
are non-uniform compounds and their metabolic effects and potency to alter plasma lipids and 453 
lipoproteins depend on the composition of SFA in their structure. As an illustration, evidence 454 
suggests that palmitate increases LDL-C and the LDL-C/HDL-C ratio and may enhance 455 
thrombogenesis, while stearate does not affect these lipoproteins; laurate increases LDL-C and 456 
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HDL-C levels, and decreases TG concentrations and the TC/HDL ratio.
124,125
 Despite the 457 
persisting belief, saturated fats per se are not robustly linked with increased all-cause mortality, 458 
CVD risk, ischemic stroke or type 2 diabetes, as concluded in several recent meta-analyses and 459 
systematic reviews.
6,20,21
 Though associated with increased LDL-C concentration, higher SFA 460 
intake mainly increases the less atherogenic lbLDL,
126,127
 confirmed also in a RCT among 461 
participants assigned to a high-fat (46% fat) compared to a low-fat (24% fat) diet for 6 462 
weeks.
128
 Conversely, partial replacement of dietary SFA with CHO, particularly with fructose 463 
and sucrose, results with production of elevated sdLDL-P and overall unfavourable effects on 464 
the lipid profile, impaired glucose tolerance and insulin resistance
14,122,129,130
. In other words, 465 
by shifting sdLDL-P towards lbLDL (phenotype B to A), dietary SFA seem to be protective 466 
against the effect of CHO.   467 
There is very little data available on the effects of different amounts of SFA on 468 
cardiometabolic risk factors in participants following a CRD. Krauss et al.
71
 found initial 469 
reduction in TG, apo-B, LDL-C, sdLDL and TC/HDL cholesterol and increased LDL peak 470 
diameter in subjects undergoing low/moderate carbohydrate intake (26% CHO) with different 471 
amounts of SFA (7-9% and 15%) during weight-loss. However, after subsequent weight loss 472 
and weight stabilisation, authors reported that improvements of these parameters were 473 
significantly greater with the 54% CHO diet. Nevertheless, this clearly confirms that a 474 
moderate short-term CHO restriction still has the potential to improve atherogenic 475 
dyslipidaemia, even in the absence of weight loss or in the presence of SFA, while the LFD 476 
seems to require weight loss for its effective improvement, as argued by Feinman & Volek.
27
 477 
Hence, based on the above supporting evidence, the fear that CRDs might have adverse health 478 
effects due to increased consumption of saturated fats in particular, would appear to be 479 
groundless. This is also pointed out in several reviews.
7,9,14
 480 
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Dietary guidelines do not only shift the population away from SFA and towards increased 481 
CHO intake, but also encourage replacement of SFA with PUFA, without stating any specific 482 
type of PUFA. The pooled effects of a meta-analysis of RCTs
131
 and 11 cohort studies
132
 483 
indeed provide evidence that substituting SFA with PUFA significantly reduces CVD events. 484 
However, substitution of SFA and trans-fats with n-6 PUFA without increasing n-3 PUFA, 485 
decreases HDL-C and increases oxidised LDL, resulting with an increased risk of all-cause 486 
mortality (mainly cancer, CVD and coronary heart disease), as reported in the meta-analysis of 487 
Ramsden et al.
133
  Thus, research and concerns should be more focused on the dietary 488 
guidelines that suggest replacing SFA with a specific dietary PUFA, as the beneficial claims 489 
regarding PUFAs in general may be even harmful as recently suggested.
14,122,130
 The 490 
macronutrient content of both CRDs and the LFDs in the RCTs included in this meta-analysis 491 
is not clearly described as they are performed on free living adults, fed ad libitum. 492 
Nevertheless, the findings of this meta-analysis in light of the presented to date available 493 
evidence demonstrate lower non-HDL-C, and lower TG/HDL-C and TC/HDL-C ratios, 494 
supporting the claim that CRDs, especially the VLCD arm are more effective in the long-term 495 
reduction of CVD risk markers. Moreover, findings also suggest that the LFD in fact presents a 496 
potential risk as it contributes towards increased atherogenic dyslipidaemia. 497 
 498 
Strengths and Limitations of the study 499 
This is the first meta-analysis that compares the long-term effects between CRD vs LFD on 500 
LDL-C levels in adults. Its strength lies in the inclusion of large RCTs (n > 100 of randomised 501 
participants) as they have more power to detect intervention effects and are more likely to 502 
generate conclusions that can be generalised. Further, the duration of follow-up was 6-24 503 
months, which enabled comparison of intervention effects at three points (6, 12 and 24 504 
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months) compared to the baseline values. Separating the CRD arm into VLCD and MLCD 505 
allowed the estimation, when possible, of the long-term effects of CRDs with different CHO 506 
content on LDL-C and other lipid parameters. However, this study has several limitations. The 507 
trials were performed on free living participants; hence the macronutrient content of both the 508 
CRD and the LFD arms remains unknown, making it impossible to separately investigate the 509 
effects of the macronutrient groups (CHO, lipids and proteins) and/or their subgroups on the 510 
outcomes of interest. Diet compliance was assessed via food diaries and 24 h diet recalls which 511 
may result in biased association due to inaccurate reporting in the trials
134,135
 and subsequent 512 
discrepancies in effect estimates in the meta-analysis
136
 which cannot be detected via the 513 
Cochrane Risk of Bias Tool.  514 
Attrition rates between the CRD and the LFD were relatively similar, although adherence was 515 
decreasing after 6 months regardless of the type of intervention. This to some extend might 516 
explain the more distinct changes of all parameters during the first six months of intervention 517 
as subjects tend to return to their baseline dietary habits, which was outlined in the long-term 518 
RCTs included in this research.
86-88
 This has also been confirmed in the three-year follow-up of 519 
a RCT
51
, that found non-significant differences in carbohydrate consumption after 36 months 520 
between participants following either a CRD or a LFD. Hence, behavioural treatments to 521 
increase long-term compliance appear to be as important as the composition of the diet in 522 
prevention and treatment of CVD risk.  Lastly, increased LDL-C may be an artefact due to the 523 
overestimation in trials where it is calculated by the Friedewald formula
94
; in cases when the 524 
TG level falls, as it happens amongst subjects on CRDs, even if TC and HDL-C remain 525 
unchanged, calculated LDL-C shows an increased level.
137
 526 
Conclusions and Implications for future research 527 
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Undoubtedly, the overall ‘picture’ of this study demonstrates that carbohydrate restriction, 528 
especially the VLCD, shows superiority over the LFD in improving cardiometabolic risk 529 
markers due to the superior effects on HDL-C and TG with only negligible effect on LDL-C 530 
and no effect on TC. These favourable outcomes from the CRD, should be considered for the 531 
prevention and management of dyslipidaemia in population groups at higher risk of 532 
cardiovascular disease (e.g. obesity/overweight, metabolic syndrome, prediabetes and type 2 533 
diabetes). The results of the presented meta-analysis suggest that the current guidelines should 534 
consider the latest evidence and carbohydrate restriction should be included as an alternative 535 
for individuals with increased cardiometabolic risk. In general, the number of well-designed 536 
large RCTs that would compare the long-term effects between the CRD and LFD on 537 
cardiometabolic risk markers in overweight and obese adults is very small. Large and long-538 
term RCTs with emphasis on psychosomatic experiences of patients and their views on 539 
motivation to undergo diet-change, focus on the quality and quantity of dietary macronutrients, 540 
more accurate assessment of the lipid profile (LDL and HDL subfractions and particle number, 541 
concentration of apolipoproteins) and inflammatory markers are warranted.  In addition, 542 
metabolomics analysis linking to the hallmark metabolite concentrations would provide an 543 
insight on a molecular level regarding inter-individual variation in response to the same dietary 544 
exposure and understanding of contradictions in data findings. Considering the epidemics of 545 
obesity and obesity related comorbidities, new nutritional approaches and more focused 546 
innovative interventions are needed in order to achieve lasting behavioural changes among 547 
population groups at higher cardiometabolic risk (obesity/overweight, metabolic syndrome, 548 
prediabetes, type 2 diabetes, and CVD). 549 
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 Table 1: PICOS criteria for inclusion of studies 
Parameter Inclusion criteria 
Population Overweight/obese adult population (18-65)  no restriction for sex  
Intervention Carbohydrate restricted diets  
Comparison Intervention vs Low-fat high-carbohydrate diet 
Outcome:  Primary 
                  Secondary  
Low density lipoprotein-cholesterol  
High density lipoprotein-cholesterol, triglycerides, total cholesterol 
Setting Randomised controlled trials with at least 100 randomised 
participants and duration of at least 6 months 
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Table 2: Reasons for exclusion of full-text trials (n = 39) 
LDL-C, low density lipoprotein-cholesterol; CVD, cardiovascular disease; SD, standard deviation; CI, 
confidence intervals. 
 
 
 
  
Reason for exclusion                        Authors     
No LDL-C reported 
 
Hu et al(2015)
45
 McManus et al(2001)
46
 Viegener et al(1990)
47
 
Zelicha et al(2017)
48
  Blüher et al(2012)138 
D. mellitus and/or CVD Shai et al (2008)
50
 Cardillo et al (2006)
51
 Tsai et al (2005)
52
 Stern 
et al (2004)53 Dyson et al (2007)54 Samaha et al (2003)55 Yancy et 
al (2010)
56
 Hu et al (2016)
57
 Turer et al (2012)
58
 Qi et al (2015)
59
 
<100 participants on start Lim et al (2010)
60
 Das et al (2007)
61
 Foster et al (2003)
62
 Seshadri 
et al (2004)
63
 Brehm et al (2003)
64
 Keogh et al (2007)
65
 Ebbeling et 
al (2007)66 Bradley et al (2009)67 Tay et al (2008)68 Dansinger et al 
(2005)
69
 Leichtle et al (2011)
70
 
Short duration (<6 months) 
 
Krauss et al (2006)
71
 Petersen et al (2006)
72
 Harvie et al (2013)
73
  
No SD / 95% CI reported 
 
Yancy et al (2004)74 Westman et al (2006)75 
Inappropriate intervention, irrelevant 
outcomes 
Jenkins et al (2007)
76
 Merra et al (2017)
77 Juanola-Falgarona et al 
(2013)
78
 Wan et al (2017)
79
 Le et al (2016)
80 Juanola-Falgarona et 
al (2014)81 Rock et al (2016)82 
High risk of bias, high dropout rate Brinkworth et al (2009)
83
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Table 3. Characteristics of included trials  
Author 
Country 
Number 
CRD / 
LFD 
Mean 
Age 
Sex 
BMI 
 
Duration 
(months) 
Intervention 
 
CRD 
 
Intervention 
 
LFD 
 
Completed 
% 
CRD/LFD 
Missing 
data 
Bazzano et 
al(2014)
84
* 
USA 
 75/73 50 
Both 
35.4 12 <40 g/d 
CHO, ad 
libitum* 
55% of energy 
from CHO, 
<30% fat 
88/79  ITT 
analysis 
Due et al 
(2008)
85
**  
Denmark 
52/48 28.2 
Both 
31.4 6 <45% energy 
from CHO, 
35-45%  
from fat, 
>20% of 
MUFA** 
20-30% 
energy from 
fat, 
50-55% 
energy from 
CHO 
56/73 ITT 
analysis 
Foster et al 
(2010)86* 
USA 
153/154 45.5 
Both 
36.1 24 Atkins 20 
g/d CHO, 
after 3 
months 
gradual 
increase of 
CHO of 5 
g/d, ad 
libitum* 
55% of energy 
from CHO, 
<30% fat, 
limited energy 
intake 
58/68 ITT 
analysis 
Frisch et al 
(2009)
87
** 
Germany 
100/100 47 
Both 
33.5 12 <40% energy 
from CHO, 
>35% from 
fat** 
>55% CHO,  
< 35% energy 
from fat 
95/89 ITT 
analysis 
Gardner et 
al 
(2007)
88
* 
USA 
77/76 
 
41.3  
F 
32 12 Atkins 20g/d 
CHO, after 3 
months 
gradual 
increase of 
CHO of 
5g/d* 
Ornish diet 
(70%  CHO, 
10% energy 
from fat) 
88/78 ITT 
analysis 
Klemsdal 
et al 
(2010)
89
** 
Norway 
100/102 46.8 
Both 
35.4 12 35-40% 
energy from 
fat, 35% 
from CHO** 
<30% energy 
from fat, 55-
60% from 
CHO 
78/84 ITT 
analysis 
Morgan et 
al 
(2009)
90
* 
UK 
57/58 40.7 
Both 
31.6 6 Atkins New 
Diet 
Revolution 
20g/d CHO, 
after 3 month 
<50 g/d 
CHO** 
Eat Yourself 
Slim –
controlled low 
fat healthy 
diet + fitness  
72  ITT 
analysis 
Sacks et al 
(2009)
91
**  
USA 
204/204 51.5 
Both 
33 24 40% energy 
from fat, 
40% from 
CHO** 
65%  CHO 
and 20%  fat, 
average 
protein 
82/83 ITT 
analysis 
*very low carbohydrate diet intervention; ** moderate low carbohydrate diet intervention 
BMI, body mass index; CRD, carbohydrate restricted diet; LFD, low fat diet; CHO, carbohydrate; MUFA, 
monounsaturated fatty acids; ITT, Intention-to-treat  
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Intervention                                    CRD 
                          
                                     LFD 
Parameter 
mmol/L 
LDL-C  
(SD) 
HDL-C 
(SD) 
TG 
(SD) 
TC 
(SD) 
LDL-C 
(SD) 
HDL-C 
(SD) 
TG 
(SD) 
TC 
(SD) 
Bazzano 
et al (2014)84  
3.20 
(0.9) 
1.40 
(0.32) 
1.30 
(0.6) 
5.1 
(1.1) 
3.30 
(1.0) 
1.22 
(0.3) 
1.40 
(0.9) 
5.3 
(1.1) 
Due et al 
(2008)
85
 
2.75 
(0.8) 
1.22 
(0.6) 
1.02 
(0.37) 
4.44 
(0.74) 
2.78  
(0.9) 
1.23 
(0.42) 
1.15 
(0.8) 
4.52 
(1.04) 
Foster et al 
(2010)86 
3.11 
(0.67) 
1.20 
(0.35) 
1.28 
(0.62) 
4.88 
(0.78) 
3.21  
(0.76) 
1.18 
(0.30) 
1.40 
(0.83) 
4.98 
(0.85) 
Frisch et al 
(2009)
87
 
3.54 
(0.8) 
1.49 
(0.37) 
1.31 
(0.56) 
5.50 
(0.93) 
3.56 
(0.91) 
1.46 
(0.37) 
1.59 
(0.65) 
5.54 
(1.10) 
Gardner 
et al (2007)88  
2.82 
(0.75) 
1.37 
(0.36) 
1.41 
(0.88) 
na 2.87 
(0.70) 
1.29 
(0.28) 
1.3 
(0.7) 
na 
Klemsdal 
et al (2010)
89
  
3.76 
(0.94) 
1.28 
(0.37) 
1.93 
(1.21) 
5.8 
(0.97) 
3.84 
(1.01) 
1.29 
(0.37) 
1.91 
(1.13) 
6.0 
(1.04) 
Morgan 
et al (2009)90  
3.72 
(0.52) 
1.22 
(0.23) 
1.65 
(0.7) 
na 3.59 
(0.67) 
1.22 
(0.3) 
1.59 
(0.83) 
na 
Sacks et al 
(2009)
91
  
3.21 
(0.85) 
1.27 
(0.39) 
1.52 
(0.92) 
5.26 
(0.96) 
3.31 
(0.83) 
1.24 
(0.1) 
1.66 
(1.05) 
5.15 
(0.98) 
CRD, carbohydrate restricted diet; LFD, low fat diet; LDL-C, low density lipoprotein cholesterol; HDL-C, high 
density lipoprotein cholesterol, TG, triglycerides; TC, total cholesterol; SD, standard deviation. 
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Figure 1. Flow diagram of literature search 
Figure 2. Quality assessment of each included study (n = 8) using the Cochrane Risk of Bias Tool 
Figure 3. Risk of bias (%) across included studies (n = 8) using the Cochrane Risk of Bias Tool: 
selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias. 
Figure 4. Forest plot for LDL-C changes between CRD and LFD at 6, 12, and 24 months compared to 
baseline (mmol/L). Abbreviations: CRD, carbohydrate restricted diet; LFD, low fat diet; LDL, low 
density lipoprotein. 
 
Figure 5. Forest plot for LDL-C changes between VLCD and LFD at 6, 12 and 24 months compared to 
baseline (mmol/L). Abbreviations: VLCD, very low carbohydrate diet; LFD, low fat diet; LDL, low 
density lipoprotein. 
 
Figure 6. Forest plot for LDL-C changes between MLCD and LFD at 6, 12 and 24 months compared to 
baseline (mmol/L). Abbreviations: MLCD, moderate low carbohydrate diet; LFD, low fat diet; LDL, 
low density lipoprotein. 
 
Figure 7. Forest plot for HDL-C changes between CRD and LFD at 6, 12 and 24 months compared to 
baseline (mmol/L). Abbreviations: CRD, carbohydrate restricted diet; LFD, low fat diet; HDL, high 
density lipoprotein. 
 
Figure 8. Forest plot for TG changes between CRD and LFD at 6, 12 and 24 months compared to 
baseline (mmol/L). Abbreviations: CRD, carbohydrate restricted diet; LFD, low fat diet; HDL, high 
density lipoprotein. 
 
Figure 9.  Forest plot for HDL-C changes between VLCD and LFD at 6, 12 and 24 months compared 
to baseline (mmol/L). Abbreviations: VLCD, very low carbohydrate diet; LFD, low fat diet; HDL, high 
density lipoprotein. 
 
Figure 10. Forest plot for TG changes between VLCD and LFD at 6, 12 and 24 months compared to 
baseline (mmol/L). Abbreviations: VLCD, very low carbohydrate diet; LFD, low fat diet; TG, 
triglycerides. 
Figure 11. Forest plot for HDL-C changes between MLCD and LFD at 6, 12 and 24 months compared 
to baseline (mmol/L). Abbreviations: MLCD, moderate low carbohydrate diet; LFD, low fat diet; HDL, 
high density lipoprotein. 
Figure 12. Forest plot for TG changes between MLCD and LFD at 6, 12 and 24 months compared to 
baseline (mmol/L). Abbreviations: MLCD, moderate low carbohydrate diet; LFD, low fat diet; TG, 
triglycerides. 
Figure 13. Forest plot for Total Cholesterol changes between CRD and LFD at 6, 12 and 24 
months compared to baseline (mmol/L). Abbreviations: CRD, carbohydrate restricted diet; LFD, 
low fat diet. 
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Figure 1. Flow diagram of literature search  
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Figure 2. Quality assessment of each included study (n = 8) using the Cochrane Risk of Bias Tool  
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Figure 3. Risk of bias (%) across included studies (n = 8) using the Cochrane Risk of Bias Tool: selection 
bias, performance bias, detection bias, attrition bias, reporting bias, and other bias.  
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Figure 4. Forest plot for LDL-C changes between CRD and LFD at 6, 12, and 24 months compared to 
baseline (mmol/L). Abbreviations: CRD, carbohydrate restricted diet; LFD, low fat diet; LDL, low density 
lipoprotein.  
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Figure 5. Forest plot for LDL-C changes between VLCD and LFD at 6, 12 and 24 months compared to 
baseline (mmol/L). Abbreviations: VLCD, very low carbohydrate diet; LFD, low fat diet; LDL, low density 
lipoprotein.  
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Figure 6. Forest plot for LDL-C changes between MLCD and LFD at 6, 12 and 24 months compared to 
baseline (mmol/L). Abbreviations: MLCD, moderate low carbohydrate diet; LFD, low fat diet; LDL, low 
density lipoprotein.  
 
 
Page 41 of 59 Nutrition Reviews
  
 
 
Figure 7. Forest plot for HDL-C changes between CRD and LFD at 6, 12 and 24 months compared to baseline 
(mmol/L). Abbreviations: CRD, carbohydrate restricted diet; LFD, low fat diet; HDL, high density lipoprotein. 
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Figure 8. Forest plot for TG changes between CRD and LFD at 6, 12 and 24 months compared to baseline 
(mmol/L). Abbreviations: CRD, carbohydrate restricted diet; LFD, low fat diet; HDL, high density lipoprotein. 
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Figure 9.  Forest plot for HDL-C changes between VLCD and LFD at 6, 12 and 24 months compared to 
baseline (mmol/L). Abbreviations: VLCD, very low carbohydrate diet; LFD, low fat diet; HDL, high density 
lipoprotein.  
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Figure 10. Forest plot for TG changes between VLCD and LFD at 6, 12 and 24 months compared to baseline 
(mmol/L). Abbreviations: VLCD, very low carbohydrate diet; LFD, low fat diet; TG, triglycerides.  
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Figure 11. Forest plot for HDL-C changes between MLCD and LFD at 6, 12 and 24 months compared to 
baseline (mmol/L). Abbreviations: MLCD, moderate low carbohydrate diet; LFD, low fat diet; HDL, high 
density lipoprotein.  
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Figure 12. Forest plot for TG changes between MLCD and LFD at 6, 12 and 24 months compared to baseline 
(mmol/L). Abbreviations: MLCD, moderate low carbohydrate diet; LFD, low fat diet; TG, triglycerides.  
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Figure 13. Forest plot for Total Cholesterol changes between CRD and LFD at 6, 12 and 24 months compared 
to baseline (mmol/L). Abbreviations: CRD, carbohydrate restricted diet; LFD, low fat diet.  
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PRISMA 2009 Checklist 
Section/topic  # Checklist item  
Reported on 
page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review registration number.  
1-2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  2-4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
5 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
Not registered 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
5-6 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
4-5 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
Supplementary 
material 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
5-6 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
6-7 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
5-6 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
6-7 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  7 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I
2
) for each meta-analysis.  
7-8 
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PRISMA 2009 Checklist 
Page 1 of 2  
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
6-7 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
7 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
8 (Figure 
1) 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
8-9 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  10 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
10-14 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  10-14 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  13-14 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  10-14 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
14-20 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
20-21 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  21-22 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
22 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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Search strategy 
 
Medline and CINAHL (EBSCO) 
 
#1 Diet, Carbohydrate-Restricted. mm 
#2    (low carbohydrate). ti, kw. 
#3    (carbohydrate N2 restrict*).ti, kw. 
#4    Ketogenic Diet. mm 
#5    (ketogenic and diet*).ti, kw. 
#6    (atkins and diet*).ti, kw. 
#7    1 or 2 or 3 or 4 or 5 or 6 
#8    Diet, Fat-Restricted. mm 
#9    (fat N2 restrict*).ti, kw. 
#10  low fat. ti, kw. 
#11  (conventional and diet*). ti, kw. 
#12  8 or 9 or 10 or 11 
#13  7 and 12 
#14  Dyslipidemias. mm 
#15  Lipoproteins. mm 
# 16  (low density lipoprotein). ti, ab 
# 17  (cholesterol). ti, ab 
# 18  (LDL*). ti, ab 
# 19  (lipid profil*). kw, ab 
# 20  (Dyslipid*). kw, ab 
# 21  (high density lipoprotein). ti, ab 
# 22  (HDL*). ti, ab 
# 23  14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 
#24  13 and 23 
# 25  (Random* controlled trial).  Pt 
# 26  (Controlled clinical trial). Pt 
# 27  Random*. ab 
# 28  Trial*. ab 
# 29  Placebo*. ab 
# 30  Group*. ab 
# 31  25 or 26 or 27 or 28 or 29 or 30 
# 32  Animals. mm not humans. mw 
# 33  31 not 32 
# 34  24 and 33 
 
 
Pubmed central 
 
#1 Diet, Carbohydrate-Restricted. mh 
#2    low carbohydrate. ti, kw. 
#3    “carbohydrate N2 restrict*”.ti, kywd. 
#4    Ketogenic Diet. mh 
#5    “ketogenic and diet*”.ti, kywd. 
#6    “atkins and diet*”.ti, kywd. 
#7    1 or 2 or 3 or 4 or 5 or 6 
#8    Diet, Fat-Restricted. mh 
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#9    “fat N2 restrict*”.ti, kywd. 
#10  low fat. ti, kywd. 
#11  “conventional and diet*”. ti, kywd. 
#12  8 or 9 or 10 or 11 
#13  7 and 12 
#14  Dyslipidemias. mh 
#15  Lipoproteins. mh 
# 16  “low density lipoprotein”. ti, ab 
# 17  “cholesterol”. ti, ab 
# 18  “LDL*”. ti, ab 
# 19  “lipid profil*”. kywd, ab 
# 20  “Dyslipid*”. kywd, ab 
# 21  “high density lipoprotein”. ti, ab 
# 22  “HDL*”. ti, ab 
# 23  14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 
#24  13 and 23 
# 25  “Random* controlled trial”.  Pt 
# 26  “Controlled clinical trial”. Pt 
# 27  Random*. ab 
# 28  Trial*. ab 
# 29  Placebo*. ab 
# 30  Group*. ab 
# 31  25 or 26 or 27 or 28 or 29 or 30 
# 32  Animals. mh not humans. mh 
# 33  31 not 32 
# 34  24 and 33 
 
 
 
Cochrane Library Trials 
 
#1 MeSH descriptor: [Diet, Carbohydrate-Restricted] 
#2    “low carbohydrate”. ti, ab, kw. 
#3    carbohydrate near/2 restrict*.ti, ab, kw. 
#4    MeSH descriptor: [Ketogenic Diet] 
#5    (ketogenic and diet*).ti, ab, kw. 
#6    (atkins and diet*).ti, ab, kw. 
#7    1 or 2 or 3 or 4 or 5 or 6 
#8    MeSH descriptor: [Diet, Fat-Restricted] 
#9    (fat near/2 restrict*).ti, ab, kw. 
#10  “low fat”. ti, ab, kw. 
#11  “conventional and diet*”. ti, ab, kw. 
#12  8 or 9 or 10 or 11 
#13  7 and 12 
#14  MeSH descriptor: [Dyslipidemias] 
#15  MeSH descriptor: [Lipoproteins] 
# 16  “low density lipoprotein”. ti, ab, kw 
# 17  “cholesterol”. ti, ab, kw 
# 18  “LDL*”. ti, ab, kw 
# 19  “lipid profil*”. kw, ab 
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# 20  “Dyslipid*”. kw, ab 
# 21  “high density lipoprotein”. ti, ab, kw 
# 22  “HDL*”. ti, ab, kw 
# 23  14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 
#24  13 and 23 
# 25  MeSH descriptor [Randomized controlled trial] 
# 26  MeSH descriptor [Controlled clinical trial] 
# 27  25 or 26  
# 28  MeSH descriptor [Animals] not MeSH descriptor [humans] 
# 29  27 not 28 
# 30  24 and 29 
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Table S1. Weighted mean difference of LDL-C, HDL-C, TG, and TC between CRD and LFD at 
6, 12 and 24 months compared to baseline (mmol/L) 
 
Outcome or Subgroup 
(mmol/L) 
Studies Participants Mean Difference 
(Random, 95% CI) 
P I
2 
Mean LDL-C change 8 3358 0.07 [0.02, 0.13] 0.009 36 
LDL- C change at 6 months 8 1633 0.08 [-0.01, 0.18] 0.08 58 
LDL-C change after 12 months 5 1010 0.04 [-0.04, 0.12] 0.37 1 
LDL-C change after 24 months 2 715 0.10 [-0.01, 0.21] 0.06 0 
Mean HDL-C change 8 3358 0.08 [0.06, 0.11] 1x10
-5
 52 
HDL-C change at 6 months 8 1633 0.09 [0.06, 0.12] 1x10
-5
 28 
HDL-C change at 12 months 5 1010 0.09 [0.02, 0.15] 0.004 74 
HDL-C change at 24 months 2 715 0.05 [-0.00, 0.11] 0.06 28 
Mean TG change 8 3358 -0.13 [-0.19, -0.08] 1x10
-5
 40 
TG change at 6 months 8 1633 -0.18 [-0.25, -0.10] 1x10
-5
 43 
TG change at 12 months 5 1010 -0.11 [-0.18, -0.03] 0.005 0 
TG change at 24 months 2 715 0.01 [-0.12, 0.13] 0.93 0 
Mean TC change 6 2937 0.00 [-0.01, -0.00] 0.002 0 
TC change at 6 months 6 1365 -0.01 [-0.01, -0.00] 0.02 0 
TC change at 12 months 4 857 -0.01 [-0.04, 0.03] 0.78 6 
TC change at 24 months 2 715 -0.00 [-0.01, 0.00] 0.66 0 
 
LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; TG, plasma triglycerides; 
TC, total cholesterol; CRD, carbohydrate restricted diet; LFD-low fat diet 
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Table S2. Weighted mean difference of LDL-C, HDL-C and TG between VLCD and LFD at 6, 12 
and 24 months compared to baseline (mmol/L) 
 
Outcome or Subgroup 
(mmol/L) 
Studies Participants Mean Difference 
(Random, 95% CI) 
P I
2 
% 
Mean LDL-C change 4 1638 0.07 [-0.05, 0.18] 0.27 75 
LDL- C change at 6 months 4 723 0.14 [-0.02, 0.30] 0.09 74 
LDL-C change after 12 months 3 608 -0.04 [-0.24, 0.16] 0.70 74 
LDL-C change after 24 months 1 307 0.08 [-0.07, 0.23] 0.29 N/A 
Mean HDL-C change 4 1638 0.12 [0.10, 0.14] 1x10
-5
 0 
HDL-C change at 6 months 4 723 0.13 [0.09, 0.16] 1x10
-5
 0 
HDL-C change at 12 months 3 608 0.13 [0.09, 0.17] 1x10
-5
 0 
HDL-C change at 24 months 1 307 0.08 [0.02, 0.14] 0.01 N/A 
Mean TG change 4 1638 -0.19 [-0.26, -0.12] 1x10
-5
 41 
TG change at 6 months 4 723 -0.24 [-0.32, -0.16] 1x10
-5
 30 
TG change at 12 months 3 608 -0.16 [-0.25, -0.06] 0.002 0 
TG change at 24 months 1 307 0.02 [-0.16, 0.20] 0.82 N/A 
 
LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; TG, plasma triglycerides; 
N/A, not applicable; VLCD, very low carbohydrate diet; LFD, low fat diet 
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Table S3. Weighted mean difference of LDL-C, HDL-C and TG between MLCD and LFD at 6, 
12 and 24 months compared to baseline (mmol/L) 
 
Outcome or Subgroup 
(mmol/L) 
Studies Participants Mean Difference 
(Random, 95% CI) 
P I
2 
% 
Mean LDL-C change 4 1720 0.05 [-0.02, 0.11] 0.16 0 
LDL- C change at 6 months 4 910 0.02 [-0.06, 0.11] 0.54 0 
LDL-C change after 12 months 2 402 0.06 [-0.17, 0.30] 0.59 60 
LDL-C change after 24 months 1 408 0.13 [-0.03, 0.29] 0.11 N/A 
Mean HDL-C change 4 1720 0.04 [0.01, 0.07] 0.005 0 
HDL-C change at 6 months 4 910 0.06 [0.02, 0.10] 0.02 0 
HDL-C change at 12 months 2 402 0.01 [-0.04, 0.06] 0.68 0 
HDL-C change at 24 months 1 408 0.02 [-0.05, 0.09] 0.52 N/A 
Mean TG change 4 1720 -0.06 [-0.13, 0.00] 0.06 0 
TG change at 6 months 4 910 -0.09 [-0.18, 0.00] 0.05 0 
TG change at 12 months 2 402 -0.04 [-0.16, 0.08] 0.5 0 
TG change at 24 months 1 408 -0.01 [-0.20, 0.18] 0.92 N/A 
 
LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; TG, plasma triglycerides; 
N/A, not applicable; MLCD, moderate low carbohydrate diet; LFD, low fat diet 
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 Figure S1: Funnel plot of the mean LDL-C differences (mmol/L) between CRD and LFD across 
trials (n=8) 
  
MD - Mean Difference of LDL-C (mmol/L) between CRD vs LFD; SE (MD) - Standard Error of the MD 
 
LDL-C, low density lipoprotein cholesterol; CRD, carbohydrate restricted diet; LFD, low fat diet 
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Figure S2: Funnel plot of the mean HDL-C differences (mmol/L) between CRD and LFD across 
trials (n=8) 
  
MD - Mean Difference of HDL-C (mmol/L) between CRD vs LFD; SE (MD) - Standard Error of the MD 
 
HDL-C, high density lipoprotein cholesterol; CRD, carbohydrate restricted diet; LFD, low fat diet 
 
 
Page 58 of 59Nutrition Reviews
Figure S3: Funnel plot of the mean TG differences (mmol/L) between CRD and LFD across trials 
(n=8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MD - Mean Difference of TG (mmol/L) between CRD vs LFD; SE (MD) - Standard Error of the MD 
TG, plasma triglycerides; CRD, carbohydrate restricted diet; LFD, low fat diet 
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